John Whalen
Epilepsy · Fleming Island, FLNPI 1093337057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for epilepsy clinicians in FL, where the typical reported total is $6,512.
Across 51 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$139
- Axsome Therapeutics, Inc.$129
- Novartis$108
- AbbVie$100
- Eisai Inc.$81
- Teva Pharmaceuticals USA, Inc.$78
- plus $551 from 15 others
What the payments were for
- Food & beverage$1,186100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 5 | $139 |
| Axsome Therapeutics, Inc. | 5 | $129 |
| Novartis | 4 | $108 |
| AbbVie | 5 | $100 |
| Eisai Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
| Genentech USA, Inc. | 3 | $70 |
| Lundbeck LLC | 3 | $68 |
| Pfizer | 3 | $55 |
| Argenx US, Inc. | 2 | $50 |
| Neurocrine Biosciences, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $45 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Boston Scientific | 1 | $32 |
| Amgen | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Neurelis, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Aucta Pharmaceuticals, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
How this compares
$1,186 in reported general payments places this provider in the 20th percentile of 23 epilepsy providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 34 | $471 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 21 | $409 |
| Levetiracetam | 17 | $300 |
| Lamotrigine | 11 | $231 |
| Pregabalin | 11 | $41 |
| Tizanidine Hcl | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Fleming Island
- Brian CostellBoca Raton$469K
- Andrew LermanMiami$249K
- Alberto Pinzon ArdilaMiami$144K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- Mohamed NasserWeston$28K
- William TatumJacksonville$28K
- Brin FreundJacksonville$18K
- Miguel Melo-BicchiMiami$15K
- Claudio OsorioTampa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.